Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Co. Uses RNA Editing as Treatment for Rare Disease
October 4, 2022 (Investorideas.com Newswire) The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Biotech Investor Stock News: NurExone (TSXV: NRX) Announces Scientific Survey Results of Proprietary Exosome-based Technology
Calgary, Alberta - October 4, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NurExone Biologic Inc. (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company's lab showing the effectiveness of the Company's proprietary small interfering RNA in inhibiting the expression of the phosphatase and tensin homolog.

Interim Results From Phase 2b Trial Are 'Encouraging'
October 3, 2022 (Investorideas.com Newswire) Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Biopharma Asks for Emergent Use in US of New COVID Drug
September 30, 2022 (Investorideas.com Newswire) The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status

US Biotech Firm Keeps Growing Revenue
September 27, 2022 (Investorideas.com Newswire) Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.

Analyst Says Buy Before Biotech Co.'s Clinical Trials
September 26, 2022 (Investorideas.com Newswire) Argenx SE has "several upcoming catalysts," noted a Wedbush report. Argenx SE's (ARGX:NASDAQ) drug for generalized myasthenia gravis

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating
September 26, 2022 (Investorideas.com Newswire) To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World
September 22, 2022 (Investorideas.com Newswire) The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.

Important Catalyst Expected Soon for Cancer Drug Co.
September 21, 2022 (Investorideas.com Newswire) The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Larger Than Current
September 21, 2022 (Investorideas.com Newswire) The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers,"

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Satellos Bioscience Inc. Announces the Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 815,750 Stock Options...

Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a joint venture company, NW Micelle Therapeutics Inc. ("NWMT"), for the purpose of developing an oral formulation of cannabidiol for the treatment of insomnia and other indications in the mental health sphere ("Oral CBD"). NWPT...

Satellos Bioscience Announces OTCQB Listing in the United States
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that its common shares have commenced trading on the OTCQB Venture Market ("OTCQB") under the symbol "MSCLF". Shares in Satellos will continue to trade on the TSXV under...

GEGR Announces the Acquisition of 50% of the Capital Shares of a Real Estate Project Financing and Development Corporation FMF GROUP SRL
Salt Lake City, Utah--(Newsfile Corp. - October 5, 2022) - Gaensel Energy Group, Inc., (OTC Pink: GEGR) ("Gaensel" or the "Company"), a diversified holding company, announces a corporate update. Gaensel Energy Group is pleased to announce the acquisition of 50% of the Capital shares of FMF GROUP SRL, an Italian real estate project financing and development corporation based in Reggio Emilia, Italy. FMF Group has been financing and developing real estate renovation projects in North...

Zonetail Inc. Announces Closing of First Tranche of Non-Brokered Private Placement; Completes Initial Closing for Proceeds of $511,790
Toronto, Ontario--(Newsfile Corp. - October 5, 2022) - Zonetail Inc. (TSXV: ZONE) ("Zonetail" or the "Company"), is pleased to announce the closing of the first tranche of its previously announced private placement. The Offering consists of units of the Company (the "Units") being issued at a price of $0.04 per Unit, with each Unit being comprised of one common share (a "Share") and one half of one (1/2) common share purchase warrant (a "Warrant"). Each...

Subscribe to Biotech News